Announcement • Jun 24
THX Pharma Announces Appointment of Sophie Jacq Lapointe to Board of Directors THX Pharma had announced the appointment of Sophie Jacq Lapointe to its Board of Directors. Sophie Jacq Lapointe brought more than twenty years of experience in the pharmaceutical and biotechnology sectors. She had held executive and strategic leadership positions at Roche, Sanofi, Sanofi Genzyme and Ipsen. She contributed to more than twenty successful product launches across France, Europe and emerging markets, including Dupixent(R) at Sanofi Genzyme, one of the group's most successful launches in Europe. Her appointment was fully aligned with THX Pharma's new strategy, which aimed to accelerate the registration, market access and international commercialization of its drug candidates for rare diseases. Her expertise in corporate strategy, portfolio development, market access and governance would be a major asset in supporting the company's next phases of growth. Sophie Jacq Lapointe was a graduate of ESSEC Business School, further completed her education with a specialization in immuno-oncology from Harvard Medical School and a corporate governance certification from the French Institute of Directors (Institut Français des Administrateurs). Announcement • May 20
THX Pharma Société Anonyme, Annual General Meeting, Jun 23, 2026 THX Pharma Société Anonyme, Annual General Meeting, Jun 23, 2026. Location: 28 rue de la redoute, fontenay aux roses France New Risk • Apr 30
New major risk - Revenue size The company makes less than US$1m in revenue. Total revenue: €813k (US$952k) This is considered a major risk. Companies with a small amount of revenue are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (15% average weekly change). Negative equity (-€1.9m). Shareholders have been substantially diluted in the past year (62% increase in shares outstanding). Revenue is less than US$1m (€813k revenue, or US$952k). Minor Risk Market cap is less than US$100m (€47.5m market cap, or US$55.6m). 
